Zibotentan/Dapagliflozin Combination Demonstrated Significant Albuminuria Reduction in Patients with Chronic Kidney Disease and Proteinuria in ZENITH-CKD Phase IIb Trial
52.5% reduction with high-dose and 47.7% reduction with low-dose combination compared to baseline, and an acceptable tolerability profile
Novel investigational drug leverages SGLT2 inhibition and high selectivity ETA receptor antagonism with...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Chronic Kidney Disease | Clinical Trials | Dapagliflozin | Forxiga | Pharmaceuticals | Proteinuria | SGLT2 Inhibitors | Urology & Nephrology